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PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer.
METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on neoadjuvant 
therapy for breast cancer and provide recommended care options.
RESULTS A total of 41 articles met eligibility criteria and form the evidentiary basis for the guideline 
recommendations.
RECOMMENDATIONS Patients undergoing neoadjuvant therapy should be managed by a multidisciplinary care 
team. Appropriate candidates for neoadjuvant therapy include patients with inflammatory breast cancer and 
those in whom residual disease may prompt a change in therapy. Neoadjuvant therapy can also be used to 
reduce the extent of local therapy or reduce delays in initiating therapy. Although tumor histology, grade, stage, 
and estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) expression should routinely 
be used to guide clinical decisions, there is insufficient evidence to support the use of other markers or genomic 
profiles. Patients with triple-negative breast cancer (TNBC) who have clinically node-positive and/or at least T1c 
disease should be offered an anthracycline- and taxane-containing regimen; those with cT1a or cT1bN0 TNBC 
should not routinely be offered neoadjuvant therapy. Carboplatin may be offered to patients with TNBC to 
increase pathologic complete response. There is currently insufficient evidence to support adding immune 
checkpoint inhibitors to standard chemotherapy. In patients with hormone receptor (HR)-positive (HR-positive), 
HER2-negative tumors, neoadjuvant chemotherapy can be used when a treatment decision can be made 
without surgical information. Among postmenopausal patients with HR-positive, HER2-negative disease, 
hormone therapy can be used to downstage disease. Patients with node-positive or high-risk node-negative, 
HER2-positive disease should be offered neoadjuvant therapy in combination with anti-HER2-positive therapy. 
Patients with T1aN0 and T1bN0, HER2-positive disease should not be routinely offered neoadjuvant therapy.
Additional information is available at www.asco.org/breast-cancer-guidelines.
J Clin Oncol 39:1485-1505. 
INTRODUCTION
Adjuvant or postoperative systemic therapy is the
mainstay of treatment for early-stage breast cancer.
The term neoadjuvant refers to the use of systemic
therapy prior to surgery. Neoadjuvant therapy was
initially used in breast cancer for the treatment of
inoperable, locally advanced disease.1 Subsequently,
the role of neoadjuvant therapy in patients with op-
erable breast cancer has been extensively investi-
gated. Building on the finding that systemic treatment
could render some inoperable patients eligible for
surgery, there was interest in using preoperative
systemic therapy to reduce the extent and morbidity of
curative surgery. Multiple studies of both chemo-
therapy and endocrine therapy have shown that
neoadjuvant treatment can increase the likelihood of
breast-conserving surgery,2-5 establishing neoadjuvant
treatment as a viable option in patients with operable
disease.
Additionally, as the goal of adjuvant treatment is to
eradicate micrometastatic disease and prevent distant
recurrence, there was interest in studying whether
delivering systemic treatment earlier could further
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Guideline Question
What is the optimal use of neoadjuvant therapy for women with invasive, nonmetastatic breast cancer?
Target Population
Patients with nonmetastatic breast cancer.
Target Audience
Medical oncologists, surgical oncologists, radiologists, pathologists, oncology nurses, patients or caregivers or advocates, and
oncology advanced practice providers.
Methods
An Expert Panel was convened to develop clinical practice guideline recommendations based on a systematic review of the
medical literature.
CLINICAL QUESTION 1
Which patients with breast cancer are appropriate candidates for neoadjuvant systemic therapy?
Recommendations
Recommendation 1.1. Neoadjuvant chemotherapy is the treatment of choice for patients with inflammatory breast cancer or
those with unresectable or locally advanced disease at presentation whose disease may be rendered resectable with
neoadjuvant treatment (Type: informal consensus; Evidence quality: low; Strength of recommendation: strong).
Recommendation 1.2. Tumor histology, grade, stage and estrogen, progesterone, and HER2 expression should routinely be
used to guide clinical decisions as to whether or not to pursue neoadjuvant chemotherapy. There is insufficient evidence to
support the use of other immunochemical markers, morphological markers (eg, tumor-infiltrating lymphocytes) or genomic
profiles to guide a clinical decision as to whether or not to pursue neoadjuvant chemotherapy (Type: informal consensus;
Evidence quality: insufficient; Strength of recommendation: moderate).
Recommendation 1.3. Neoadjuvant systemic therapy should be offered to patients with high-risk HER2-positive or triple-
negative breast cancer (TNBC) in whom the finding of residual disease would guide recommendations related to adjuvant
therapy (Type: evidence-based; benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).
Recommendation 1.4. Neoadjuvant systemic therapy may be offered to reduce the extent of surgery (breast-conserving
surgery and axillary lymph node dissection). Chemotherapy with or without targeted therapy, or endocrine therapy (if hormone
receptor–positive [HR-positive]) may be offered (Type: evidence-based; benefits outweigh harms; Evidence quality: inter-
mediate; Strength of recommendation: moderate).
Recommendation 1.5. In patients for whom a delay in surgery is preferable (eg, for genetic testing required for surgical
treatment decision making, to allow time to consider reconstructive options) or unavoidable, neoadjuvant systemic therapy
may be offered (Type: informal consensus; benefits outweigh harms; Evidence quality: low; Strength of recommendation:
moderate).
CLINICAL QUESTION 2
How should response be measured in patients receiving neoadjuvant chemotherapy?
Recommendations
Recommendation 2.1. Patients receiving neoadjuvant therapy should be monitored for response with clinical examination at
regular intervals. Breast imaging may be used to confirm clinical suspicion of progression and for surgical planning. When
imaging is used, the modality that was most informative at baseline—mammography, ultrasound, or magnetic resonance
imaging—should be used at follow-up (Type: informal consensus; Evidence quality: insufficient; Strength of recommendation:
moderate).
Recommendation 2.2. Blood- and tissue-based biomarkers should not be used for monitoring patients receiving neoadjuvant
therapy (Type: informal consensus; Evidence quality: insufficient; Strength of recommendation: strong).
Recommendation 2.3. Pathologic complete response (pCR), defined as absence of invasive disease in breast and lymph
nodes, should be used to measure response to guide clinical decision making (Type: informal consensus; Evidence quality:
insufficient; Strength of recommendation: moderate).
(continued on following page)
studies completed in the 1990s by the National Surgical
Adjuvant Breast and Bowel Project (NSABP; studies B-18
and B-27) investigated whether administering chemo-
therapy prior to surgery would improve outcomes
compared with adjuvant treatment.2,3 These studies
showed no difference in disease-free survival (DFS) or
overall survival (OS) based on the timing of systemic
therapy. However, they did show that patients who
THE BOTTOM LINE (CONTINUED)
CLINICAL QUESTION 3
What neoadjuvant systemic therapy regimens are recommended for patients with TNBC?
Recommendations
Recommendation 3.1. Patients with TNBC who have clinically node-positive and/or at least T1c disease should be offered an
anthracycline- and taxane-containing regimen in the neoadjuvant setting (Type: evidence-based; benefits outweigh harms;
Evidence quality: high; Strength of recommendation: strong).
Recommendation 3.2. Patients with cT1a or cT1bN0 TNBC should not routinely be offered neoadjuvant therapy outside of a
clinical trial (Type: evidence-based; benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).
Recommendation 3.3. Carboplatin may be offered as part of a neoadjuvant regimen in patients with TNBC to increase
likelihood of pCR. The decision to offer carboplatin should take into account the balance of potential benefits and harms (Type:
evidence-based; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).
Recommendation 3.4. There is insufficient evidence to recommend routinely adding the immune checkpoint inhibitors to
neoadjuvant chemotherapy in patients with early-stage TNBC (Type: informal consensus; Evidence quality: intermediate;
Strength of recommendation: moderate).
CLINICAL QUESTION 4
What neoadjuvant treatment is recommended for patients with HR-positive/HER2-negative breast cancer?
Recommendations
Recommendation 4.1. Neoadjuvant chemotherapy can be used instead of adjuvant chemotherapy in any patient with
HR-positive, HER2-negative breast cancer in whom the chemotherapy decision can be made without surgical pathology data and/
or tumor-specific genomic testing (Type: informal consensus; Evidence quality: low; Strength of recommendation: moderate).
Recommendation 4.2. For postmenopausal patients with HR-positive/HER2-negative disease, neoadjuvant endocrine therapy
with an aromatase inhibitor may be offered to increase locoregional treatment options. If there is no intent for surgery,
endocrine therapy may be used for disease control (Type: evidence-based; benefits outweigh harms; Evidence quality:
intermediate; Strength of recommendation: moderate).
Recommendation 4.3. For premenopausal patients with HR-positive/HER2-negative early-stage disease, neoadjuvant en-
docrine therapy should not be routinely offered outside of a clinical trial (Type: evidence-based; benefits outweigh harms;
Evidence quality: intermediate; Strength of recommendation: moderate).
CLINICAL QUESTION 5
What neoadjuvant treatment is recommended for patients with HER2-positive disease?
Recommendations
Recommendation 5.1. Patients with node-positive or high-risk node-negative, HER2-positive disease should be offered
neoadjuvant therapy with an anthracycline and taxane or non–anthracycline-based regimen in combination with trastuzumab.
Pertuzumab may be used with trastuzumab in the neoadjuvant setting (Type: evidence-based, benefits outweigh harms;
Evidence quality: high; Strength of recommendation: strong).
Recommendation 5.2. Patients with T1a N0 and T1b N0, HER2-positive disease should not be routinely offered neoadjuvant
chemotherapy or anti-HER2 agents outside of a clinical trial (Type: informal consensus; Evidence quality: intermediate;
Strength of recommendation: moderate).
Additional Resources
More information, including a supplement with additional evidence tables, slide sets, and clinical tools and resources, is
available at www.asco.org/breast-cancer-guidelines. The Methodology Manual (available at www.asco.org/guideline-
methodology) provides additional information about the methods used to develop this guideline. Patient information is
available at www.cancer.net.
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients
should have the opportunity to participate.
achieved a pathologic complete response (pCR) had a
significantly better prognosis than those who had residual
disease, and long-term data from these trials and subse-
quent meta-analyses suggested that there may be sub-
populations of patients who experienced benefit from
neoadjuvant treatment.6 The CTNeoBC pooled analysis of
neoadjuvant breast cancer clinical trials published in 2014
confirmed that achievement of a pCR with neoadjuvant
treatment was prognostic, and it also showed that the
association between pCR and outcomes was strongest in
patients with triple-negative and human epidermal growth
factor receptor 2 (HER2)–positive disease.7,8
More recently, interest in neoadjuvant therapy has focused
on examining the role of response to neoadjuvant treatment
as a predictive marker. The question of whether im-
provement in pCR from the addition of a particular treat-
ment translates to a benefit in long-term outcome has
generated substantial controversy. In the trial-level analysis
of CTNeoBC, there was no significant association between
an increase in the rate of pCR with specific therapies and
event-free survival, and thus a predictive effect could not be
confirmed.7 It should be noted that therapeutic neo-
adjuvant trials that include pCR or change in a biomarker,
such as Ki67, as the primary end point are often done to
guide drug development, and are not meant to change the
standard of care until confirmatory trials evaluating survival
outcomes are performed. These proof-of-principle studies
will not be discussed in detail in this guideline and are not
intended to change routine practice.
As our understanding of the biology of breast cancer has
evolved in recent decades, it has become clear that optimal
therapy for breast cancer is driven by subtype. Thus, older
neoadjuvant trials that used a one-size-fits-all approach to
therapy selection are less relevant in the current era of bi-
ologically driven treatment selection. As noted, it has long
been known that patients with triple-negative and HER2-
positive disease are more likely to achieve pCR with neo-
adjuvant treatment. In this context, a number of recent trials
have focused on using a lack of response to neoadjuvant
therapy to identify patients who have a worse prognosis and
could therefore benefit from additional adjuvant treatment.9,10
The purpose of this guideline is to develop recommenda-
tions concerning the optimal use of systemic neoadjuvant
therapy, including chemotherapy, endocrine therapy, and
targeted therapy for patients with invasive breast cancer. The
Expert Panel strongly advocates for a multidisciplinary team
management approach when considering neoadjuvant
therapy for patients with breast cancer. The guideline out-
lines recommendations based on clinical presentation,
patient characteristics, and breast cancer subtype.
GUIDELINE QUESTIONS
This clinical practice guideline addresses five overarching
clinical questions: (1) Which patients with breast cancer are
appropriate candidates for neoadjuvant systemic therapy?
(2) How should response bemeasured in patients receiving
neoadjuvant chemotherapy? (3) What neoadjuvant sys-
temic therapy regimens are recommended for patients with
triple-negative breast cancer (TNBC)? (4) What neo-
adjuvant treatment is recommended for patients with
HER2-negative/HR-positive breast cancer? (5) What neo-




This systematic review-based guideline product was de-
veloped by a multidisciplinary Expert Panel, which included
a patient representative and ASCO guidelines staff with
health research methodology expertise. The Expert Panel
met face-to-face and via teleconference and/or webinar and
corresponded through e-mail. Based upon the consider-
ation of the evidence, the authors were asked to contribute to
the development of the guideline, provide critical review, and
finalize the guideline recommendations. The guideline
recommendations were sent for an open comment period of
2 weeks (August 28, 2020, through September 8, 2020)
allowing the public to review and comment on the recom-
mendations after submitting a confidentiality agreement.
These comments were taken into consideration while fi-
nalizing the recommendations. Members of the Expert Panel
were responsible for reviewing and approving the penulti-
mate version of the guideline, which was then circulated for
external review, and submitted to the Journal of Clinical
Oncology (JCO) for editorial review and consideration for
publication. All ASCO guidelines are ultimately reviewed and
approved by the Expert Panel and the ASCOClinical Practice
Guidelines Committee prior to publication. All funding for the
administration of the project was provided by ASCO.
The recommendations were developed by using a sys-
tematic review (January 1, 2000-August 31, 2020) of
randomized phase II and phase III clinical trials (RCTs) in
PubMed. The search was restricted to articles published in
English, and to systematic reviews, meta-analyses, and
randomized controlled trials that reported on pCR and
survival end points. (Broader outcome criteria, including
clinical tumor objective response, were used for studies of
neoadjuvant endocrine therapy.) The electronic literature
searches were supplemented by articles from Panel
members’ personal files to inform selected clinical questions
for which no contemporary or directly relevant RCTs were
available. The ASCO Guidelines Methodology Manual
(available at www.asco.org/guideline-methodology) pro-
vides additional information about the guideline develop-
ment process.
This is the most recent information as of the publication
date. Articles were excluded from the systematic review if
they were (1) meeting abstracts not subsequently published
in peer-reviewed journals; (2) editorials, commentaries,
letters, news articles, case reports, and narrative reviews;
(3) published in a non-English language; (4) RCTs with
, 100 patients total across treatment arms; (5) trials that
evaluated only clinical response, biomarker end points, or
breast-conserving surgery (BCS) feasibility or rates; and (6)
reports of exploratory or secondary analyses. Based on the
implementability review, revisions were made to the draft to
clarify recommended actions for clinical practice. Ratings
for the type and strength of recommendation, evidence, and
potential bias are provided with each recommendation. The
ASCO Expert Panel and guidelines staff will work with co-
chairs to keep abreast of any substantive updates to the
guideline. Based on formal review of the emerging litera-
ture, ASCO will determine the need for updates.
Guideline Disclaimer
The Clinical Practice Guidelines and other guidance
published herein are provided by the American Society of
Clinical Oncology, Inc (ASCO) to assist providers in clinical
decision making. The information herein should not be
relied upon as being complete or accurate, nor should it be
considered as inclusive of all proper treatments or methods
of care or as a statement of the standard of care. With the
rapid development of scientific knowledge, new evidence
may emerge between the time information is developed
and when it is published or read. The information is not
continually updated and may not reflect the most recent
evidence. The information addresses only the topics spe-
cifically identified therein and is not applicable to other
interventions, diseases, or stages of diseases. This infor-
mation does not mandate any particular course of medical
care. Further, the information is not intended to substitute
for the independent professional judgment of the treating
provider, as the information does not account for individual
variation among patients. Recommendations reflect high,
moderate, or low confidence that the recommendation
reflects the net effect of a given course of action. The use of
words like “must,” “must not,” “should,” and “should not”
indicates that a course of action is recommended or not
recommended for either most or many patients, but there is
latitude for the treating physician to select other courses of
action in individual cases. In all cases, the selected course
of action should be considered by the treating provider in
the context of treating the individual patient. Use of the
information is voluntary. ASCO provides this information on
an “as is” basis and makes no warranty, express or implied,
regarding the information. ASCO specifically disclaims any
warranties of merchantability or fitness for a particular use
or purpose. ASCO assumes no responsibility for any injury
or damage to persons or property arising out of or related to
any use of this information, or for any errors or omissions.
Guideline and Conflicts of Interest
The Expert Panel was assembled in accordance with
ASCO’s Conflict of Interest Policy Implementation for
Clinical Practice Guidelines (“Policy,” found at http://
www.asco.org/rwc). All members of the Expert Panel com-
pleted ASCO’s disclosure form, which requires disclosure of
financial and other interests, including relationships with
commercial entities that are reasonably likely to experience
direct regulatory or commercial impact as a result of pro-
mulgation of the guideline. Categories for disclosure include
employment; leadership; stock or other ownership; hono-
raria, consulting, or advisory role; speaker’s bureau; research
funding; patents, royalties, other intellectual property; expert
testimony; travel, accommodations, expenses; and other
relationships. In accordance with the Policy, the majority of
the members of the Expert Panel did not disclose any re-
lationships constituting a conflict under the Policy.
RESULTS
A total of 46 articles representing 36 unique RCTs met
eligibility criteria and form the evidentiary basis for the
guideline recommendations. The randomized phase II and
III trials included in the review are summarized in the Data
Supplement Table 1 (online only).9-25,26-55 The included
RCTs addressed the use of neoadjuvant systemic therapy
in patients with high-risk HER2-positive or TNBC; specific
neoadjuvant systemic therapy regimens in patients with
TNBC; use of immune checkpoint inhibitors in the treat-
ment of early-stage TNBC; neoadjuvant endocrine therapy
in postmenopausal patients with HR-positive, HER2-neg-
ative breast cancer; preoperative endocrine therapy for
premenopausal patients with HR-positive, HER2-negative
breast cancer; neoadjuvant therapy for patients with node-
positive or high-risk node-negative, HER2-positive disease;
and, more broadly, the efficacy of neoadjuvant chemo-
therapy regimens in nonmetastatic breast cancer. The
electronic search identified 20 meta-analyses5,56-68 that
provided confirmatory, supplementary evidence (Table 2
in the Data Supplement, online only).
Study quality was formally assessed for the 29 phase III RCTs
identified (Table 3 in the Data Supplement, online only).
Design aspects related to the individual study quality were
assessed by one reviewer, with factors such as blinding,
allocation concealment, placebo control, intention to treat,
funding sources, etc, generally indicating a low to inter-
mediate potential risk of bias for most of the identified evi-
dence. Follow-up times varied between studies, lowering the
comparability of the results. Refer to Methodology Manual
for definitions of ratings for overall potential risk of bias.
RECOMMENDATIONS
Clinical Question 1
Which patients with breast cancer are appropriate candi-
dates for neoadjuvant systemic therapy?
Recommendation 1.1. Neoadjuvant chemotherapy is the
treatment of choice for patients with inflammatory breast
cancer (IBC) or those with unresectable or locally advanced
disease at presentation whose disease may be rendered re-
sectablewith neoadjuvant treatment (Type: informal consensus;
Evidence quality: low; Strength of recommendation: strong).
Recommendation 1.2. Tumor histology, grade, stage and
estrogen, progesterone, and HER2 expression should rou-
tinely be used to guide clinical decisions as to whether or not
to pursue neoadjuvant chemotherapy. There is insufficient
evidence to support the use of other immunochemical
markers, morphological markers (eg, tumor-infiltrating lym-
phocytes [TILs]), or genomic profiles to guide a clinical
decision as to whether or not to pursue neoadjuvant che-
motherapy (Type: informal consensus; Evidence quality:
insufficient; Strength of recommendation: moderate).
Recommendation 1.3. Neoadjuvant systemic therapy
should be offered to patients with high-risk HER2-positive
or TNBC in whom the finding of residual disease would
guide recommendations related to adjuvant therapy (Type:
evidence-based; benefits outweigh harms; Evidence quality:
high; Strength of recommendation: strong).
Recommendation 1.4. Neoadjuvant systemic therapy may
be offered to reduce the extent of surgery (BCS and axillary
lymph node dissection). Chemotherapy with or without
targeted therapy, or endocrine therapy (if HR-positive) may
be offered (Type: evidence-based; benefits outweigh
harms; Evidence quality: intermediate; Strength of rec-
ommendation: moderate).
Recommendation 1.5. In patients for whom a delay in
surgery is preferable (eg, for genetic testing required for
surgical treatment decision making, to allow time to con-
sider reconstructive options) or unavoidable, neoadjuvant
systemic therapy may be offered (Type: informal consen-
sus; benefits outweigh harms; Evidence quality: low;
Strength of recommendation: moderate).
Literature review and analysis. Patients with inoperable
locally advanced breast cancer (LABC) or IBC. There are no
modern large randomized clinical trials that focus specif-
ically on patients with IBC or LABC, and these patients are
often excluded from trials of adjuvant and neoadjuvant
therapy. The recommendation for neoadjuvant therapy in
these patients represents the best clinical opinion of the
Expert Panel based on data from phase II trials, older
published nonrandomized data, expert consensus opinion,
and clinical experience.
Clinical interpretation. Neoadjuvant systemic therapy of-
fers a range of potential advantages for patients with LABC
or IBC, including downstaging of the primary tumor to bring
to operability; more prompt treatment of subclinical distant
micrometastases; and enhanced ability to evaluate in vivo
the response of the tumor to particular systemic agents.69
Literature review and analysis. Use of immunohistochemi-
cal markers or genomic profiles to guide neoadjuvant
therapy clinical decisions. There are no randomized trials
that directly address the use of genomic profiles to guide
neoadjuvant therapy decisions. The Expert Panel’s rec-
ommendation against the use of nonroutine immunohis-
tochemical markers, morphological markers (eg, TILs), or
genomic profiles to guide clinical decision making re-
garding neoadjuvant chemotherapy represents the best
clinical opinion of the Expert Panel based on the currently
limited prospective data.
Clinical interpretation. Both Oncotype DX Recurrence
Score andMammaPrint have been shown to predict benefit
from adjuvant chemotherapy, and retrospective studies
reported that high-risk OncotypeDX Recurrence Scoremay
be associated with a higher pCR rate.70 However, no
prospective trials have assessed the clinical utility of ge-
nomic markers for determining whether patients should
receive their systemic chemotherapy prior to surgery or for
selecting a chemotherapy regimen. Estrogen, progester-
one, and HER2 expression are routinely used in practice to
guide use of targeted therapies. Other immunochemical
markers, morphological markers, and genomic profile
markers have been used in research, but do not have
sufficient evidence to support their use for guiding neo-
adjuvant therapy clinical decision making.
Literature review and analysis. Use of neoadjuvant systemic
therapy in patients with high-risk HER2-positive or TNBC.
The systematic review identified two studies that support
the use of neoadjuvant systemic therapy in patients with
high-risk HER2-positive or TNBC in whom the finding of
residual disease would prompt a change in adjuvant
therapy. The Capecitabine for Residual Cancer as Adjuvant
Therapy (CREATE-X) open-label, phase III trial10 evaluated
the safety and efficacy of adjuvant chemotherapy in pa-
tients with HER2-negative primary breast cancer who had
residual invasive disease after they had received neo-
adjuvant chemotherapy that contained taxane, anthracy-
cline, or both. CREATE-X randomly assigned 910 patients
to receive standard postoperative adjuvant treatment either
with capecitabine or without. Analyses revealed that ad-
juvant capecitabine prolonged both DFS and OS. In safety
analyses, the most frequent adverse event observed in the
capecitabine group was hand-foot syndrome; this occurred
in 325 of 443 patients (73.4%). In the subset of patients
with triple-negative disease—about 30% of patients
studied—the DFS rate was 69.8% among patients who
received capecitabine versus 56.1% in the control group
(hazard ratio [HR], 0.58; 95% CI, 0.39 to 0.87); the OS rate
was 78.8% versus 70.3% (HR, 0.52; 95%CI, 0.30 to 0.90).
In the subset of patients with HR-positive breast cancer,
there were numerical improvements in DFS and OS that did
not meet statistical significance. The DFS rate was 76.4% in
the capecitabine group and 73.4% in the control group (HR
for recurrence, second, cancer, or death, 0.81; 95% CI,
0.55 to 1.17), and OS rates were 93.4% and 90%, re-
spectively (HR for death, 0.73; 95% CI, 0.38 to 1.40).
The KATHERINE open-label, phase III clinical trial com-
pared adjuvant trastuzumab emtansine (T-DM1) with
trastuzumab in patients with stage I to III, HER2-positive
breast cancer who had residual invasive disease in the
breast or axilla after completing neoadjuvant chemotherapy
plus HER2-targeted therapy.9 Patients were randomly
assigned to receive either postoperative T-DM1 (n 5 743)
at a dose of 3.6 mg per kilogram of body weight, or tras-
tuzumab (n 5 743) at a dose of 6 mg per kilogram in-
travenously every 3 weeks for 14 cycles (42 weeks). A
majority of patients (80%) received trastuzumab as their
sole HER2-targeted therapy in the neoadjuvant setting;
approximately 18% received dual neoadjuvant HER2-
targeted therapy with trastuzumab and pertuzumab. In-
vasive disease or death occurred in 91 (12.2%) of patients
who received adjuvant T-DM1 and in 165 (22.2%) patients
who received trastuzumab. The estimated invasive DFS at 3
years was significantly higher in the T-DM1 group than in
the trastuzumab group (88.3% v 77%; HR, 0.50; 95% CI,
0.39 to 0.64; P , .001). Similarly, the risk of distant re-
currence was lower in patients who received T-DM1 than in
patients who received trastuzumab (HR, 0.60; 95% CI,
0.45 to 0.79). Grade 3 or higher adverse events occurred in
190 (25.7%) patients who received T-DM1 and in 111
(15.4%) of patients who received trastuzumab, including
thrombocytopenia (5.7% v 0.3%) and peripheral sensory
neuropathy (1.4% v 0%). Serious adverse events occurred
in 94 patients (12.7%) in the T-DM1 group and in 58
patients (8.1%) in the trastuzumab group. Adverse events
leading to discontinuation of T-DM1 included thrombocy-
topenia, elevated liver function test abnormalities, and
peripheral sensory neuropathy. Patients who were unable
to complete T-DM1 received trastuzumab to complete a
year of HER2-targeted therapy.
Clinical interpretation. The CREATE-X and KATHERINE
trials establish that, in patients with TNBC or HER2-positive
disease, the presence or absence of residual disease after
neoadjuvant therapy alters treatment recommendations in
the adjuvant setting. Thus, neoadjuvant therapy is the
treatment of choice in all but small, node-negative, TNBC,
or HER2-positive tumors.
Literature review and analysis. Neoadjuvant therapy to re-
duce local therapy. A response to neoadjuvant therapy can
result in downstaging of a tumor and therefore can improve
tumor resectability, enhance cosmesis, and reduce post-
operative complications.71 Evidence for the reduction in the
extent of local therapy associated with neoadjuvant che-
motherapy comes from several large-scale randomized
trials that compared neoadjuvant and adjuvant chemo-
therapy in patients with early-stage breast cancer. The
National Surgical Adjuvant Breast and Bowel Project
(NSABP B-18),72,73 the European Cooperative Trial in
Operable breast cancer trial,74 and European Organization
for Research and Treatment of Cancer Trial 10902,75 all
reported increased rates of BCS with neoadjuvant, com-
pared with adjuvant chemotherapy. A number of Phase III
neoadjuvant studies, including CALGB 40601,76 CALGB
40603,77 and BrighTNess,4 included prespecified sec-
ondary analyses to assess whether patients deemed not to
be candidates for BCS at baseline were able to be con-
verted to BCS. In these trials, the conversion rate from BCS-
ineligible to BCS-eligible ranged from 43% to 53%.
There are fewer studies that address the use of neoadjuvant
treatment to reduce axillary surgery. Limited data indicate
that in patients with nodal metastases, downstaging be-
cause of neoadjuvant chemotherapy may allow for less
extensive surgery for the axilla and thereby reduce surgical
complications such as lymphedema and dysesthesias.78-80
Because the randomized trials that directly address this
question are ongoing, the recommendation for neoadjuvant
therapy to permit less extensive surgery on the axilla thus
represents the best clinical opinion of the Expert Panel based
on personal experience in breast cancer management.
Clinical interpretation. For resectable disease, neoadjuvant
systemic therapy with appropriate adjuvant regimens im-
proves breast conservation rates and may reduce the need
for axillary lymphadenectomy. In HR-positive, HER2-
negative breast cancer, neoadjuvant endocrine therapy
has similar clinical response rates to chemotherapy and is a
reasonable option. However, tumor eradication in either the
breast or axillary lymph nodes is rare for this tumor subtype.
Literature review and analysis. Neoadjuvant therapy in
cases of surgical delay. There are no randomized trials that
directly address the use of neoadjuvant therapy as a bridge
to delayed surgery. The recommendation that neoadjuvant
therapy can be used when a surgical delay is preferred or
necessary represents thebest clinical opinion of the Expert Panel
based on personal experience in breast cancer management.
Clinical interpretation. In resource-constrained settings
and during public health crises such as the 2020 COVID-19
pandemic, there can be limited access to healthcare re-
sources, including surgery. In these situations, neoadjuvant
therapy can be used both to control local disease and
prevent distant spread of disease until surgery can be
performed.81,82
Additionally, there are clinical situations in which a delay of
surgery, although not absolutely necessary, may be pre-
ferred. For example, if a patient with a clear indication for
chemotherapy has a suspectedBRCA1 orBRCA2mutation
and is considering bilateral mastectomy, it may be rea-
sonable to delay surgery until genetic testing results are
available or until reconstructive options can be discussed.
In this scenario, as neoadjuvant therapy and adjuvant
therapy have been shown to be equivalent in terms of long-
term outcomes,2 neoadjuvant therapy may be considered.
Clinical Question 2
How should response be measured in patients receiving
neoadjuvant chemotherapy?
Recommendation 2.1. Patients receiving neoadjuvant
therapy should be monitored for response with clinical
examination at regular intervals. Breast imaging may be
used to confirm clinical suspicion of progression and for
surgical planning. When imaging is used, the modality that
was most informative at baseline—mammography, ultra-
sound, or magnetic resonance imaging—should be used at
follow-up (Type: informal consensus; Evidence quality:
insufficient; Strength of recommendation: moderate).
Recommendation 2.2. Blood- and tissue-based biomarkers
should not be used for monitoring patients receiving
neoadjuvant therapy (Type: informal consensus; Evidence
quality: insufficient; Strength of recommendation: strong).
Recommendation 2.3. pCR, defined as absence of invasive
disease in breast and lymph nodes, should be used to
measure response to guide clinical decision making (Type:
informal consensus; Evidence quality: insufficient; Strength
of recommendation: moderate).
Literature review and analysis. There are no data from
randomized trials informing the optimal methods for
monitoring response during treatment. The recommen-
dations for the frequency and character of monitoring
clinical, radiologic, and pathologic response and for
management of progressive disease (PD) reflect the best
clinical opinion of the Expert Panel based on personal
experience in breast cancer management.
Clinical interpretation. For patients favoring BCS after
neoadjuvant chemotherapy, strong consideration should
be given to performing imaging, both at baseline and at
completion of chemotherapy for optimal surgical plan-
ning.83 However, there is no evidence to support the benefit
of routine imaging for progression, because of the infre-
quent nature of PD. If PD is suspected clinically, additional
imaging is recommended for confirmation. Imaging should
be performed with the same modality that was used for
baseline assessment; studies have shown that MRI pro-
vides the most accurate objective measure of extent of
disease.83,84 If there is evidence of clinical progression,
then a multidisciplinary decision should be made regard-
ing switching therapies or proceeding to locoregional
intervention.
There are no data regarding the use of blood markers (eg,
CA27-29 and CA15-3) for monitoring response to treat-
ment, and these are not recommended for use in the
neoadjuvant setting. Several studies have evaluated the
association between early reductions in biomarkers (eg,
Ki67) and improved breast cancer outcomes; however,
these approaches are used for research purposes and to
justify the evaluation of new therapeutic approaches, and
are not meant to guide routine clinical care.85
Most neoadjuvant studies use pCR as the primary end
point. However, there is substantial variation as to whether
residual noninvasive disease is included in the definition of
pCR. In the KATHERINE and CREATE-X studies, pCR was
defined as a lack of residual invasive disease. Studies have
also evaluated and validated the use of residual cancer
burden and yP American Joint Committee on Cancer
(AJCC) staging prognostic factors associated with long-term
breast cancer outcomes.86,87 There is scant evidence from
randomized clinical trials to inform the question of how
progression on neoadjuvant treatment is defined and
managed, as trials have not had a consistent approach.
Progression while on neoadjuvant treatment is rare and not
well studied; in the largest reported series, only 3% of
patients had confirmed PD, with over half of progressing
patients demonstrating PD within the first two cycles of
neoadjuvant treatment.88 However, progression during
neoadjuvant chemotherapy is associated with a signifi-
cantly worse progression-free survival and OS,88 high-
lighting the importance of clinical monitoring during
treatment.
Although there have been no clinical trials that have
compared different methodologies for examining the tumor
bed, there is a wealth of data that show that the finding of
pCR (whether defined as absence of invasive disease or
absence of invasive and noninvasive disease in breast and
lymph nodes) is associated with a favorable prognosis.
Importantly, pCR is critical for determining the need for
additional adjuvant therapy in TNBC and HER2-positive
breast cancer. When surgery is performed after neo-
adjuvant systemic treatment, meticulous clinical, radio-
logic, and pathologic correlation should be performed to
ensure that the tumor bed has been examined thoroughly
for residual disease, and extent of disease in the breast and
axilla should be indicated in the pathology report using yP
AJCC staging. Information from imaging and localization
markers inserted is particularly helpful for accurate pa-
thology evaluation of mastectomy specimens, and speci-
men radiography is an important capability to direct that
sampling.
Clinical Question 3
What neoadjuvant systemic therapy regimens are recom-
mended for patients with TNBC?
Recommendation 3.1. Patients with TNBC who have clin-
ically node-positive and/or at least T1c disease should be
offered an anthracycline- and taxane-containing regimen in
the neoadjuvant setting (Type: evidence-based; benefits
outweigh harms; Evidence quality: high; Strength of rec-
ommendation: strong).
Recommendation 3.2. Patients with cT1a or cT1bN0 TNBC
should not routinely be offered neoadjuvant therapy outside
of a clinical trial (Type: evidence-based; benefits outweigh
harms; Evidence quality: high; Strength of recommenda-
tion: strong).
Recommendation 3.3. Carboplatin may be offered as part
of a neoadjuvant regimen in patients with TNBC to increase
likelihood of pCR. The decision to offer carboplatin should
take into account the balance of potential benefits and
harms (Type: evidence-based; benefits outweigh harms;
Evidence quality: intermediate; Strength of recommenda-
tion: moderate).
Recommendation 3.4. There is insufficient evidence to
recommend routinely adding the immune checkpoint in-
hibitors to neoadjuvant chemotherapy in patients with early-
stage TNBC (Type: informal consensus; Evidence quality:
intermediate; Strength of recommendation: moderate).
Literature review and analysis. Neoadjuvant chemotherapy
in patients with TNBC. There is no direct evidence from
phase III randomized clinical trials regarding the optimal
neoadjuvant chemotherapy regimen in patients with TNBC.
However, there is broad consensus based on key ran-
domized clinical trials6 and an individual patient data meta-
analysis89 that chemotherapy regimens appropriate for
adjuvant treatment by stage are also appropriate for neo-
adjuvant treatment. On this basis, the Expert Panel rec-
ommends that patients with clinically node-positive and/or
at least T1c TNBC be offered an anthracycline- and taxane-
based neoadjuvant regimen.
There is less agreement concerning the addition of car-
boplatin to the standard anthracycline-based neoadjuvant
chemotherapy regimen in patients with TNBC. In high-risk
patients, the addition of platinum to the standard neo-
adjuvant chemotherapy regimen of paclitaxel and AC
(doxorubicin and cyclophosphamide) or EC (epirubicin and
cyclophosphamide) has been shown consistently to im-
prove pCR rates,11-13,56,57,59 by up to 20%.90 The meta-
analysis by Poggio et al56 of nine RCTs (2,109 patients) that
evaluated the safety and efficacy of platinum-based versus
platinum-free neoadjuvant chemotherapy in patients with
TNBC found, for instance, that platinum-based neo-
adjuvant chemotherapy increased pCR rates significantly
from 37.0% to 52.1% (odds ratio [OR], 1.96; 95% CI, 1.46
to 2.62, P , .001). Not surprisingly, there was a signifi-
cantly greater risk of grade 3 and 4 hematological adverse
events observed with platinum-based neoadjuvant che-
motherapy. Petrelli et al59 found a similar increased pCR
rate in a meta-analysis of RCTs that investigated platinum-
based neoadjuvant chemotherapy in TNBC. Neoadjuvant
chemotherapy that contained carboplatin or cisplatin sig-
nificantly increased the pCR rate compared with non–
platinum-containing neoadjuvant chemotherapy (relative
risk [RR], 1.45; 95% CI, 1.25 to 1.68; P , .0001).
However, the effect of adding platinums on long-term
outcomes such as DFS and OS is much less certain.91
None of the relevant trials has been adequately powered to
evaluate survival outcomes. In CALGB 40603 (Alliance),12
carboplatin significantly improved pCR breast or axilla
(54% v 41%, P 5 .0029) in patients with stage II-III TNBC
when added to weekly paclitaxel for 12 weeks followed by
AC once every 2 weeks for four cycles. In patients who
received carboplatin, grade $ 3 thrombocytopenia and
neutropenia occurred more commonly; these patients were
also more likely to require dose modification, skipped
doses, or early treatment discontinuation because of toxicity.
Patients who achieved a pCR had improved event-free survival
and OS compared with patients who did not achieve a pCR at a
median 3-year follow-up.92 There was no improvement in
survival outcome, however, with the addition of carboplatin to
the standard neoadjuvant chemotherapy regimen.
The GeparSixto randomized phase II clinical trial included
patients with stage II or III HER2-positive (n5 273) or TNBC
(n 5 315). Patients received 18 weeks of neoadjuvant
weekly paclitaxel, weekly nonpegylated liposomal doxoru-
bicin, and bevacizumab every 21 days, and were randomly
assigned to either concurrent weekly carboplatin or no ad-
ditional treatment. Those who received carboplatin had an
improvement in pCR (pCR 53.2% with carboplatin v 36.9%
without carboplatin, P5 .005).13 Treatment discontinuation
wasmore frequent in patients who received carboplatin than
in those who did not receive carboplatin (48% v 39%).
Loibl et al11 reported the results of a phase III, double-blind,
placebo-controlled trial (BrighTNess) that evaluated the
addition of the poly (ADP-ribose) polymerase (PARP) in-
hibitor, veliparib, and carboplatin or carboplatin alone
compared with standard neoadjuvant taxane-based che-
motherapy followed by AC in patients with stage II-III TNBC.
The study randomly assigned 316 patients to paclitaxel
plus carboplatin plus veliparib; 160 patients to paclitaxel
plus carboplatin; and 158 patients to paclitaxel alone. The
pCR rates were 58% in patients who received paclitaxel and
carboplatin; 53% in patients who received paclitaxel,
carboplatin, and veliparib; and 31% in patients who re-
ceived paclitaxel alone. The difference between the latter
two groups was statistically significant (P , .0001). Not
surprisingly, grade 3 or 4 toxicities (eg, anemia, neu-
tropenia, and thrombocytopenia) occurred more frequently
among patients who received carboplatin. Event-free sur-
vival and OS were secondary end points in this trial and
have not been reported yet.
Literature review and analysis. Use of immune checkpoint
inhibitors in the treatment of early-stage TNBC. There has
been increasing interest in studying the efficacy and safety
of immunotherapy in many solid tumors, breast cancer
among them.93 Pembrolizumab and atezolizumab have
both been studied in the metastatic setting, and atezoli-
zumab is FDA-approved for first-line treatment of PD-L1–
positive TNBC and several phase II trials have suggested
increased pCR rates.94 The systematic literature review
conducted for this guideline identified two phase III ran-
domized clinical trials that addressed the role of immune
checkpoint inhibitors in the treatment of nonmetastatic
TNBC.14,51 The KEYNOTE-522 randomized, double-blind,
phase III trial evaluated the combination of carboplatin or
paclitaxel with or without pembrolizumab followed by AC
with or without pembrolizumab in patients with stage II or
stage III TNBC.14 At the second interim analysis with a
median duration of follow-up of 15.5 months, the data
showed that adding pembrolizumab to carboplatin or
paclitaxel significantly improved pCR rates. The percentage
of patients with a pCR in the pembrolizumab plus neo-
adjuvant chemotherapy group was 64.8% (260 of 401
patients) versus 51.2% in the placebo plus neoadjuvant
chemotherapy group (103 of 201 patients; estimated
treatment difference, 13.6 percentage points; 95% CI, 5.4
to 21.8; P , .001). The investigators also reported the
preliminary event-free survival rate in the two arms with 104
of the 327 expected events needed for the final analysis.
The estimated percentage of patients at 18 months who
were alive without disease progression that precluded
definitive surgery, without local or distant recurrence and
without a second primary tumor, was 91.3% (95% CI, 88.8
to 93.3) for patients in the pembrolizumab-chemotherapy
group and was 85.3% (95% CI, 80.3 to 89.1) for patients in
the placebo-chemotherapy group. Treatment-related ad-
verse events that were grade 3 or higher occurred in 76.8%
and 72.2% of the patients in the pembrolizumab-
chemotherapy group and the placebo-chemotherapy
group, respectively. The most commonly occurring grade
3 or greater adverse events in both treatment groups were
anemia, neutropenia, febrile neutropenia, and decreased
neutrophil count. Hypothyroidism, hyperthyroidism, and
adrenal insufficiency were more commonly noted in pa-
tients who received pembrolizumab.
The IMpassion031 randomized, double-blind, phase III
neoadjuvant treatment trial evaluated atezolizumab versus
placebo combined with nab-paclitaxel followed by AC in
patients with early-stage TNBC.51 Analyses revealed that
adding atezolizumab to nab-paclitaxel followed by AC im-
proved the pCR rate significantly irrespective of patients’
PD-L1 status: pCR was observed in 95 of 165 patients in
the atezolizumab plus chemotherapy group (58%; 95% CI,
50 to 65) versus in 69 of 168 patients in the placebo plus
chemotherapy group (41%; 34 to 49; rate difference 17%,
95% CI, 6 to 27; one-sided P 5 .0044). The trial was not
powered for long-term survival outcomes (event-free survival
and OS). Serious, treatment-related adverse events occurred
in 37 (23%) patients in atezolizumab plus chemotherapy
group and in 26 (16%) patients in chemotherapy plus
placebo group. Commonly reported ($ 20% incidence)
adverse events were similar between the two treatment
groups and mostly driven by chemotherapy effects.
Clinical interpretation. The choice of neoadjuvant regimen
should be appropriate to the stage and subtype of disease.
Outside of a clinical trial, regimens for neoadjuvant treat-
ment of TNBC mirror the adjuvant regimens, and generally
involve polychemotherapy with both an anthracycline and a
taxane. The addition of platinum agents during the taxane
component augments the pCR rate so may be considered
for high clinical risk, for example, node-positive disease;
however, it is not known whether the addition of platinum
improves invasive DFS or OS. In lower-risk patients or those
with cardiac risk factors in whom the risks associated with
an anthracycline may be more worrisome, a taxane-based
regimen such as docetaxel plus cyclophosphamide or
carboplatin given for six cycles may be substituted.95 Im-
mune checkpoint inhibitors added to chemotherapy in
TNBC may augment pCR, although long-term outcomes
and toxicity in patients receiving these drugs in the neo-
adjuvant setting are still undergoing evaluation.
Clinical Question 4
What neoadjuvant treatment is recommended for patients
with HR-positive/HER2-negative breast cancer?
Recommendation 4.1. Neoadjuvant chemotherapy can be
used instead of adjuvant chemotherapy in any patient with
HR-positive/HER2-negative breast cancer in whom the
chemotherapy decision can be made without surgical
pathology data and/or tumor-specific genomic testing
(Type: informal consensus; Evidence quality: low; Strength
of recommendation: moderate).
Recommendation 4.2. For postmenopausal patients with
HR-positive/HER2-negative disease, neoadjuvant endo-
crine therapy with an aromatase inhibitor may be offered to
increase locoregional treatment options. If there is no intent
for surgery, endocrine therapy may be used for disease
control (Type: evidence-based; benefits outweigh harms;
Evidence quality: intermediate; Strength of recommenda-
tion: moderate).
Recommendation 4.3. For premenopausal patients with
HR-positive/HER2-negative early-stage disease, neo-
adjuvant endocrine therapy should not be routinely offered
outside of a clinical trial (Type: evidence-based; benefits
outweigh harms; Evidence quality: intermediate; Strength
of recommendation: moderate).
Literature review and analysis. Neoadjuvant chemotherapy
in patients with HR-positive/HER2-negative breast cancer.
There is no direct evidence from randomized phase III
clinical trials to inform a recommendation regarding the
optimal neoadjuvant chemotherapy regimen in patients
with HR-positive/HER2-negative breast cancer. The rec-
ommendation that neoadjuvant chemotherapy can be used
instead of adjuvant chemotherapy in any patient with HR-
positive/HER2-negative disease is based on extrapolation
from data from the landmark NSABP B-18 trial,2 which
showed no difference between adjuvant and neoadjuvant
treatment in DFS or OS in patients with stage II or stage III
breast cancer who were randomly assigned to AC either
before or after surgery. In general, the same patient and
disease factors that are used to guide adjuvant systemic
therapy decision making (eg, nodal status, tumor grade,
and comorbidities) can be used to select patients with
HR-positive/HER2-negative disease for whom neoadjuvant
chemotherapy is appropriate.96 However, it is recognized
that some factors, such as nodal status, may be better
assessed following definitive surgery in some patients.
Further, as noted in Recommendation 1.2 in the present
guideline, the clinical utility of immunohistochemical
markers such as Ki67 and genomic predictors such as
Oncotype Dx Recurrence Score has not been definitively
determined in the neoadjuvant setting, and these markers
should not be used routinely to determine the sequence
surgery and systemic therapy.
Literature review and analysis. Neoadjuvant endocrine
therapy in postmenopausal patients with HR-positive/HER2-
negative breast cancer. The systematic literature review
identified two randomized clinical trials15,52 and one meta-
analysis5 that inform the question of neoadjuvant endocrine
therapy in postmenopausal patients with HR-positive/
HER2-negative breast cancer. The IMPACT (Immediate
Preoperative Anastrozole, Tamoxifen, or Combined With
Tamoxifen) double-blind clinical trial randomly assigned
330 postmenopausal women with estrogen receptor–positive
(ER-positive), nonmetastatic, invasive, operable breast cancer
to neoadjuvant anastrozole (n5 113), tamoxifen (n5 108), or
a combination of anastrozole and tamoxifen (n 5 109).15
There were no statistically significant differences among the
three treatment groups in tumor objective response, the
primary end point of the trial (anastrozole, 37%; tamoxifen,
36%; and the combination, 39%). Analyses of data on sur-
gical outcomes revealed that among patients initially thought
to require mastectomy, a significantly higher proportion of
patients were deemed by their surgeon to be eligible for BCS
after treatment with anastrozole (46%) versus with tamoxifen
(22%, P 5 .03). Semiglazov et al52 compared randomly
assigned patients to either neoadjuvant endocrine therapy
(anastrozole or exemestane) or chemotherapy (doxorubicin
and taxane) for 3 months and showed equivalent rates of
clinical objective response (64% in both arms), pCR (3% v
6%), and a slightly higher rate of breast-conserving surgery in
the endocrine therapy arm (33% v 24%, P 5 .058).
Spring et al5 conducted a literature-based meta-analysis of
20 prospective, randomized clinical trials (3,490 unique
patients) to evaluate the effects of neoadjuvant endocrine
therapy on clinical response rate and BCS rates in patients
with ER-positive breast cancer. Trials in the meta-analysis
had to have included at least one neoadjuvant endocrine
therapy arm. The primary end point was response rate, al-
though the authors also extracted data on pCR and BCS
rates, when reported. Eighteen of the 20 trials included only
postmenopausal women; one included premenopausal
women and postmenopausal women; and one trial included
just premenopausal women. Neoadjuvant aromatase inhib-
itors were more effective (better clinical response rate and
BCS rate) than tamoxifen based on analysis of the results of
seven trials. There were no differences observed in clinical
response rate between endocrine monotherapy and dual
endocrine therapy. The meta-analysis also suggested that
response rates and BCS rates with aromatase inhibitor-based
neoadjuvant endocrine monotherapy were comparable with
those observed with combination neoadjuvant chemother-
apy. Toxicity was significantly greater in the neoadjuvant
chemotherapy arms of the three studies examined.
Literature review and analysis. Preoperative endocrine
therapy for premenopausal patients with HR-positive/HER2-
negative breast cancer. The systematic review identified two
randomized clinical trials that investigated preoperative en-
docrine therapy among premenopausal womenwith operable
HR-positive/HER2-negative breast cancer.17,53 The Study of
Tamoxifen or Arimidex, combined with Goserelin acetate, to
compare Efficacy and safety (STAGE) evaluated neoadjuvant
tamoxifen plus goserelin (n 5 99) versus neoadjuvant
anastrozole plus goserelin (n5 98) in premenopausal women
with ER-positive, early-stage breast cancer.17 In the group that
received anastrozole plus goserelin, 69 of 98 (70.4%) patients
had a complete or partial response compared with 50 of 99
(50.5%) patients in the group that received tamoxifen plus
goserelin (estimated difference between groups 19.9%, 95%
CI, 6.5 to 33.3; P 5 .004). No significant differences were
observed in the quality-of-life measures, although the study
was not powered to detect differences in these outcome
measures. Eighty-four percent of patients reported treatment-
related adverse versus 77% of patients in the tamoxifen
group. However, adjuvant trials report that ovarian function
suppression with endocrine therapy is associated with more
toxicity with prolonged use than tamoxifen alone.97
In a randomized phase III study, Kim et al53 compared
24 weeks of neoadjuvant chemotherapy with neoadjuvant
endocrine therapy using tamoxifen and goserelin. The
primary end point of the study was clinical response rate as
determined by caliper measurement and MRI. The final
analysis included 174 patients. Response rate was sig-
nificantly higher in patients who received chemotherapy
using both caliper measurement (83.9% v 71.3%,
P5 .046) and MRI (83.7% v 52.9%, P, .001). Grade 3 or
worse treatment-related toxicities were reported in 19 pa-
tients on the chemotherapy arm and none on the endocrine
therapy arm.
Literature review and analysis. Neoadjuvant endocrine
therapy for patients with HR-positive/HER2-negative breast
cancer who are not candidates for chemotherapy or surgery.
There is no direct evidence from randomized clinical trials
regarding the question of endocrine therapy among pa-
tients with HR-positive/HER2-negative breast cancer who
are either not candidates for chemotherapy or surgery or
who decline these treatment options. The recommendation
that endocrine therapy with or without intent for surgery
may be offered to HR-positive/HER2-negative patients who
are not candidates for chemotherapy or surgery represents
the best clinical opinion of the Expert Panel based on
personal experience in breast cancer management.98
Endocrine therapy without intent for surgery has typically
been reserved for patients who are poor surgical candidates
and medically unfit for chemotherapy.99,100 In this context,
ASCO’s geriatric assessment (GA) guideline has highlighted
the importance of assessment of underlying health status
for older patients using formal GA and life expectancy tools
to help guide decisions regarding chemotherapy.101
Clinical interpretation. For HR-positive/HER2-negative
patients, neoadjuvant chemotherapy may be given if the
tumor stage is such that chemotherapy will be given re-
gardless of surgical timing; in this case, the same regimen
should be used as would be considered following sur-
gery.102 If pathologic information from the surgical resection
(ie, nodal status) or a genomic profile is needed to deter-
mine whether or not chemotherapy is appropriate, neo-
adjuvant chemotherapy should not be used. The use of
genomic assays to determine neoadjuvant chemotherapy
vs neoadjuvant endocrine therapy has not been rigorously
studied and is not recommended. Neoadjuvant endocrine
therapy with an aromatase inhibitor in postmenopausal
women has similar activity as chemotherapy and can be
considered in larger tumors for which tumor downstaging is
desired; however, significant pathologic response is rare.
Neoadjuvant endocrine therapy has been studied less
rigorously in premenopausal women, but existing data
indicate that neoadjuvant endocrine therapy is likely less
effective than chemotherapy if downstaging is desired. The
optimal duration of neoadjuvant endocrine therapy is not
known and accordingly should be individualized and
guided by careful evaluation of the patient’s clinical status
and the clinical response over time. Most studies that re-
ported downstaging of tumors with neoadjuvant endocrine
therapy administered 3-6 months of treatment.
Clinical Question 5
What neoadjuvant treatment is recommended for patients
with HER2-positive disease?
Recommendation 5.1. Patients with node-positive or high-
risk node-negative, HER2-positive disease should be of-
fered neoadjuvant therapy with an anthracycline and tax-
ane or non–anthracycline-based regimen in combination
with trastuzumab. Pertuzumab may be used with trastu-
zumab in the neoadjuvant setting (Type: evidence-based,
benefits outweigh harms; Evidence quality: high; Strength
of recommendation: strong).
Recommendation 5.2. Patients with T1a N0 and T1b N0,
HER2-positive disease should not be routinely offered
neoadjuvant chemotherapy or anti-HER2 agents outside of
a clinical trial (Type: informal consensus; Evidence quality:
intermediate; Strength of recommendation: moderate).
Literature review and analysis. Neoadjuvant therapy for
patients with node-positive or high-risk node-negative,
HER2-positive disease. Meta-analyses and RCTs of neo-
adjuvant therapy in patients with node-positive or high-risk
node-negative, HER2-positive breast cancer support the
use of an anthracycline-based chemotherapy regimen and
trastuzumab, with or without pertuzumab for dual anti-
HER2 blockade (ACTH 6 P); or the use of a non-
anthracycline chemotherapy and trastuzumab, again, with
or without pertuzumab (TCH 6 P).23 Meta-analyses of
single-agent trastuzumab studies have consistently dem-
onstrated an advantage of adding this agent to neoadjuvant
chemotherapy.58 In a pooled analysis of data from two
phase III RCTs, Petrelli et al58 reported that adding tras-
tuzumab to anthracycline-taxane chemotherapy resulted in
an increase in pCR rates, ranging from 20% to 43% (RR,
2.07; 95% CI, 1.41 to 3.03; P 5 .0002), and a decrease in
relapse rate, ranging from 20% to 12% (RR, 0.67; 95% CI,
0.48 to 0.94). von Minckwitz et al,60 in a pooled analysis
that included trastuzumab in four arms (total of 614 HER2-
positive patients), found that the odds of pCR increased
3.2-fold in patients with HER2-positive breast cancer
treated with trastuzumab during neoadjuvant chemother-
apy (P , .001). There was no association observed,
however, between the number of trastuzumab cycles and
pCR rates (OR, 1.20; 95% CI, 0.79 to 1.81; P 5 .39).
Meta-analyses have also revealed that, compared with
single-agent anti-HER2 therapy, dual anti-HER2 inhibition
significantly increases pCR rates in combination with neo-
adjuvant chemotherapy.61-66,103 Nagayama et al,64 for ex-
ample, conducted a network meta-analysis that combined
data from ten studies—a total of 2,247 patients in seven
different treatment arms—to evaluate the safety and efficacy
of neoadjuvant therapy for HER2-positive breast cancer.
The anti-HER2 agents studied were lapatinib, trastuzumab,
and pertuzumab. These authors found no statistically sig-
nificant differences among the various dual targeting ther-
apy arms; but, compared with other treatment arms,
patients in dual targeting arms had a statistically significantly
higher pCR rate (OR, 2.29; 95%credibility interval5 1.02 to
5.02; P5 .02). Nagayama et al64 concluded that, for HER2-
positive breast cancer treated in the neoadjuvant setting,
dual targeting with anti-HER2 agents plus chemotherapy
demonstrated a statistically significantly greater number of
patients with pCR than chemotherapy alone, single anti-
HER2 targeting with chemotherapy, or dual targeting
without chemotherapy. In an updated analysis of this net-
work meta-analysis that combined data from 13 studies
(total of 3,160 patients in seven different treatment arms),
Nakashoji et al61 confirmed that, in the neoadjuvant setting,
the combination of two anti-HER2 agents and chemother-
apy is most effective against HER2-positive breast cancer.
More recently, Chen et al103 evaluated the efficacy and
safety of trastuzumab plus pertuzumab vs. trastuzumab
alone added to chemotherapy in the neoadjuvant treatment
of operable HER2-positive breast cancer. The authors
identified 26 studies (a total of 9,872 patients) published
between 2005 to 2018. The combination of trastuzumab
and pertuzumab was found to significantly improve pCR
(OR, 1.33; 95% CI, 1.08 to 1.63; P 5 .006).
The individual RCTs identified by the literature search
conducted for the guideline were, with a few exceptions,
included in one or more of the meta-analyses reviewed and
are not further summarized here (see corresponding evidence
summary tables in Table 1, Data Supplement). As mentioned
previously, considered together, data from these trials sup-
port either the use of an anthracycline-based chemotherapy
regimen plus trastuzumab, or the use of a nonanthracycline
chemotherapy and trastuzumab9,18-21,24,28,32,36 in patients
with node-positive or high-risk node-negative, HER2-positive
disease. The Expert Panel further recognizes that the ad-
dition of pertuzumab to these regimens is an option (ACTH6
P or TCH 6 P). This is based on data from NeoSphere, a
randomized phase II trial of neoadjuvant pertuzumab and
trastuzumab,22,23 and the subsequent accelerated (now full)
FDA approval in the neoadjuvant setting. Although the ad-
dition of pertuzumab resulted in an increase in pCR, it should
be noted that the confirmatory APHINITY trial in adjuvant
setting resulted in a small improvement in invasive DFS in the
overall study population. The effect was most pronounced in
the lymph node-positive population, in whom there was a
4.5% improvement in invasive DFS with the addition of
pertuzumab.104
The randomized, open-label phase II NeoSphere trial
compared trastuzumab plus docetaxel (group A, n 5 107)
versus pertuzumab and trastuzumab plus docetaxel (group
B, n5 107) versus pertuzumab and trastuzumab (group C,
n5 107) versus pertuzumab plus docetaxel (group D, n5
96) administered for 12 weeks followed by an anthracycline
plus trastuzumab-based regimen in women with locally
advanced, inflammatory, or early-stage HER2-positive
breast cancer in the neoadjuvant setting.22 pCR in the
breast was the primary trial end point. Results indicated
that patients who received pertuzumab and trastuzumab
plus docetaxel had a significantly improved pCR rate (49 of
107 patients; 45.8% [95% CI, 36.1 to 55.7]) compared
with patients who received trastuzumab plus docetaxel (31
of 107; 29.0% [20.6 to 38.5]; P 5 .0141). Febrile neu-
tropenia and leukopenia were the most common grade 3 or
higher adverse events. Groups A, B, and D had about the
same proportion of serious adverse events (10%-17% of
patients); group C, those who did not initially receive cy-
totoxic therapy, had the lowest pCR rates and a lower
proportion of serious adverse events (4% of patients). In a
subsequent publication, Gianni et al23 reported NeoSphere
5-year progression-free survival (PFS), DFS, and safety
results. The PFS and DFS findings were presented for
descriptive purposes only because the trial was not pow-
ered to detect survival outcomes differences. Analyses of
PFS and DFS revealed no statically significant differences
in these long-term outcomes associated with adding per-
tuzumab to trastuzumab and docetaxel. The safety profile
observed in the 5-year analysis of NeoSphere data was
consistent with that of the primary analysis.
The randomized, multicenter, open-label, phase III KRIS-
TINE trial compared the potentially less toxic regimen of
T-DM1 plus pertuzumab with docetaxel, carboplatin, and
trastuzumab plus pertuzumab in the neoadjuvant setting.29
This study found that significantly more patients who re-
ceived the chemotherapy-containing regimen (TCH-P)
achieved a pCR than patients who received T-DM1 plus
pertuzumab (55.7% v 44.4%; P 5 .016). The T-DM1 plus
pertuzumab arm was associated with fewer grade 3-4
adverse events and fewer serious adverse events, as well
as with longer maintenance of patient-reported health-
related quality of life and physical function. Because of
the lower pCR rate, the Expert Panel does not recommend
the use of the neoadjuvant T-DM1 plus pertuzumab in
patients with node-positive or high-risk node-negative,
HER2-positive disease.
Literature review and analysis. Neoadjuvant therapy and
patients with T1a N0 and T1b N0, HER2-positive breast
cancer. Patients with T1a and T1b tumors have not been
included in trials of neoadjuvant therapy, and therefore there
are no data on whether these patients benefit from neo-
adjuvant treatment. The recommendation against the use of
neoadjuvant therapy in these patients represents, in part, the
best clinical opinion of the Expert Panel based on personal
experience in breast cancer management, which indicates
little potential for additional clinical benefit from neoadjuvant
versus adjuvant treatment in this group, and concern about
overtreatment. The concern about overtreatment is based on
results from the multicenter phase II Adjuvant Paclitaxel and
Trastuzumab (APT) trial that administered weekly paclitaxel
and trastuzumab for 12 weeks, followed by 9 months of
trastuzumab, to 406 patients with node-negative (98.5%),
HER2-positive breast cancer, 49.5% of whom had T1mic
(2.2%), T1a (16.7%), or T1b (30.5%) tumors.105 At 3 years,
analyses showed a risk of early disease recurrence of, 2%;
the survival free from invasive disease was 98.7% (95% CI,
97.6 to 99.8). Longer-term results of the APT trial were
published in 2019.106 The 7-year breast cancer-specific
survival was 98.6% (95% CI, 97.0 to 100).
There is uncertainty with regard to patients with T1c N0
disease, as these patients were included in both the APT
de-escalation trial and the KATHERINE trial.9,105,106
Depending on the clinical circumstances, these patients
could be considered for neoadjuvant chemotherapy. The
advantage is that there may be additional benefit from
T-DM1 if patients do not have a pCR9; however, there is a
risk of overtreatment based on the results of APT.105,106
Clinical interpretation. Independent of the cytotoxic che-
motherapy backbone, the addition of trastuzumab alone to
neoadjuvant chemotherapy increases pCR rates 2- to 3-fold
and is the foundation of HER2-directed therapy. The ad-
dition of a second HER2-targeted therapy further increases
rates of pCR, but the absolute benefit is varied, with patients
who have HR-negative disease and node-positive disease
appearing to benefit most. Treatment of HER2-positive
breast cancer epitomizes the goal of tailored therapy with
escalation and de-escalation strategies. HER2-targeted
therapy combined with chemotherapy in the neoadjuvant
setting, followed by adjuvant T-DM1 if residual disease is
found, illustrates appropriate escalation for high-risk dis-
ease. By contrast, utilization of the APT regimen in the
adjuvant setting for stage I disease demonstrates currently
implemented de-escalation. Ongoing studies will continue
to clarify additional de-escalation approaches in the neo-
adjuvant setting.
FUTURE RESEARCH
Most neoadjuvant clinical trials use pCR as the primary end
point. A plethora of data has shown that patients who have a
pCR have an excellent prognosis. However, as several trials
have demonstrated, improvements in pCR rate in the
neoadjuvant setting do not always translate into large dif-
ferences in breast cancer outcomes, thus promising
therapies need long-term confirmatory data. It is not fea-
sible to test all new treatment strategies in the adjuvant
setting, as each trial takes thousands of patients and many
years of follow-up. Trials in the neoadjuvant setting, such as
the I-SPY2 trial and studies of CDK4/6 inhibitors in com-
bination with endocrine therapy, may serve to identify the
most promising treatment approaches to bring forward into
adjuvant trials.107-111 Additionally, it is clear that patients
with residual disease after neoadjuvant chemotherapy have
a worse outcome. This population serves as an ideal group
in whom new therapies or treatment escalation strategies
should be studied. Numerous trials will inform a more
personalized approach to both escalation and de-
escalation using neoadjuvant therapy response.
PATIENT AND CLINICIAN COMMUNICATION
For recommendations and strategies to optimize patient-
clinician communication, see Patient-Clinician Communi-
cation: ASCO Consensus Guideline.112 Communication
topics of particular relevance to neoadjuvant therapy for
breast cancer include the need to (a) clarify the goals of
treatment so that the patient understands likely outcomes
and can relate the goals of treatment to their goals of care
(eg, downstaging to enable BCS and desire for immediate
surgery); and (b) ensure the patient’s understanding of the
potential benefits and burdens of any proposed treatment.
Communicating the goals of treatment with patients in the
neoadjuvant setting can be challenging. Patients for whom
neoadjuvant treatment is proposed begin treatment very
quickly after diagnosis, which leaves very little time to ask
questions about the therapy they are about to receive. Many
patients feel like they do not receive adequate information
to make decisions or manage the side effects of neo-
adjuvant therapy.113
Clinicians should make sure patients understand why
neoadjuvant therapy is being offered. The goals of
treatment—for example, increasing operability, allowing
time for genetic test results, or individualizing adjuvant
treatment—should be clearly communicated. Informing
patients about the rationale for neoadjuvant therapy and its
benefits can help decrease anxiety since patients may
perceive receiving neoadjuvant therapy as a delay in
necessary surgery.
Many patients and their friends and family may not un-
derstand the benefit and necessity for neoadjuvant therapy
without an explanation of the difference between local
therapy (surgery) and systemic therapy (chemotherapy,
endocrine therapy, and targeted therapy). For example, it is
much easier for patients to understand that removing the
cancer from the breast will eliminate the threat of it
spreading. Some patients may feel that leaving the cancer
in the breast while receiving neoadjuvant therapy is un-
settling.113 It is important to explain that systemic therapy
not only treats the tumor in the breast but also treats any
tumor cells that may have spread out of the breast (sub-
clinical). In addition, it is helpful to inform patients about
clinical trials that have shown that it does not matter if
chemotherapy is given before or after surgery.
Although one of the benefits of neoadjuvant therapy is
seeing one’s cancer respond to the therapy, there remains
the possibility that the tumor does not shrink during neo-
adjuvant therapy. Therefore, it is important to inform patients
how the tumor is monitored during neoadjuvant therapy and
what will happen if the tumor does not respond or grows
during therapy. Choosing a method and frequency for
monitoring tumor shrinkage or growth should be a decision
agreed upon by both clinicians and patients to decrease
anxiety for the patients. In addition, clinicians should talk to
patients about the side effects that they may experience
during neoadjuvant therapy early during treatment and allow
time for questions. This is particularly challenging in patients
who receive therapy soon after their initial diagnosis, as
there is not a lot of time to process information before
therapy begins. Many patients can feel unprepared, since
they go from being healthy to being very ill from therapy in a
short period of time.113 The emotional support and man-
agement of treatment follows a different timeline and path
during neoadjuvant therapy compared with the much more
commonly used adjuvant therapy, which can leave patients
feeling unprepared and unsupported.
A recommendation for neoadjuvant therapy ideally involves
a multidisciplinary team, including medical oncology,
surgery, radiology, and radiation oncology. Unfortunately,
not all patients have ready access to a multidisciplinary
setting. It is therefore crucial for the clinicians and
healthcare system to promote multidisciplinary treatment of
patients with breast cancer. As breast cancer treatment
becomes more personalized, more patients may be able to
benefit from neoadjuvant therapy.
When clinicians are talking with their patients about neo-
adjuvant therapy, they should use plain language to describe
complicated terms; say, for example, “therapy before surgery”
instead of “neoadjuvant therapy,” and say “therapy after
surgery” instead of “adjuvant therapy.” Also, when talking
about the purpose to de-escalate or escalate therapy based
upon their tumor’s response to neoadjuvant therapy, use the
term “optimizing therapy,” to determine whether they will
need additional therapy or usual care. Since there is still a lot to
learn about how to optimize treatments for patients with breast
cancer who receive neoadjuvant therapy, patients should be
asked to participate in clinical trials when available.
HEALTH DISPARITIES
Although ASCO clinical practice guidelines represent ex-
pert recommendations on the best practices in disease
management to provide the highest level of cancer care, it is
important to note that many patients continue to have
limited access to medical care. Racial and ethnic dispar-
ities in health care contribute significantly to this problem in
the United States. Patients with cancer who aremembers of
racial or ethnic minorities suffer disproportionately from
comorbidities, experience more substantial obstacles to
receiving care, are more likely to be uninsured, and are at
greater risk of receiving care of poor quality than other
Americans. Many other patients lack access to care be-
cause of their geographic location and distance from ap-
propriate treatment facilities. Awareness of these disparities
in access to care should be considered in the context of this
clinical practice guideline, and healthcare providers should
strive to deliver the highest level of cancer care to these
vulnerable populations.114
The electronic literature search conducted to inform this
section of the neoadjuvant therapy guideline identified 14
articles (from a total of 101 abstracts) on the topic of health
disparities.88,115-127 The available studies evaluated asso-
ciations between a range of clinical and sociodemographic
factors and the use and outcomes of neoadjuvant therapy
for breast cancer. Killelea et al,122 for example, examined
racial differences in the frequency and outcomes of neo-
adjuvant chemotherapy use and reported that neoadjuvant
chemotherapy was given more frequently to African
American, Hispanic, and Asian women than to White
women (P 5 .001). African American women, compared
with White women, had a lower pCR rate for HR-negative,
HER2-positive breast cancer (43% v 54%, P 5 .001) and
for TNBC (37% v 43%, P, .001). Bagegni et al116 similarly
found in a study of patients with TNBC who were treated
with neoadjuvant chemotherapy that African American
race, in addition to patient age, clinical stage, year of di-
agnosis, and Charlson-Deyo comorbidity score, predicted
non-pCR status. By contrast, O’Neil et al115 found that in
South Africa, women were less likely to receive neoadjuvant
chemotherapy than patients with breast cancer of Asian,
White, or mixed race (OR, 0.49; 95% CI, 0.25 to 0.96). In a
survey of 8 US Medical Centers, Neuner et al118 found that
lower income was strongly associated with less receipt of
neoadjuvant chemotherapy: NACT receipt was lower for
those with income, $100,000 in US dollars (adjusted OR,
0.56; 95% CI, 0.2 to 0.9). Also of concern, Knisely et al117
reported that White patients were more likely to complete
neoadjuvant chemotherapy than non-White patients (OR,
3.65, P 5 .014).
Another set of studies examined the associations of racial
and ethnic factors with clinical outcomes of breast cancer
neoadjuvant therapy. Pastoriza et al119 investigated asso-
ciations among distant recurrence, race, and type of
chemotherapy (adjuvant chemotherapy or neoadjuvant
chemotherapy) in a sample of women with localized or
LABC. They reported that African American patients who
were treated with neoadjuvant chemotherapy had worse
distant recurrence-free survival than African American
patients treated with adjuvant chemotherapy, or than White
patients treated with either neoadjuvant chemotherapy or
adjuvant chemotherapy. In a study of pretreatment pre-
dictors of tumor progression during neoadjuvant chemo-
therapy for breast cancer, Caudle et al88 found that, along
with high nuclear grade, advanced tumor stage, and high
Ki-67 score, African American race (P 5 .002) was pre-
dictive of PD. Ju et al124 investigated a range of disease and
demographic factors associated with recurrence in a
population of patients with breast cancer who had achieved
a pCR with neoadjuvant chemotherapy. In a binary multiple
logistic regression model, race emerged as the only inde-
pendent predictor of recurrence—African American
women were five times more likely to develop recurrence of
their breast cancer. Howard-McNatt et al125 evaluated PFS
and OS in White and African American women with breast
cancer who received neoadjuvant chemotherapy. Their
analyses showed worse 5-year PFS for African American
women compared with White women (58% v 78%, re-
spectively, P5 .05); there was no difference in OS between
these two groups (P5 .095). Interpretation of these studies
is challenging as multiple disease-related factors as well as
social determinants of care may be affecting outcomes
independent of the use of neoadjuvant chemotherapy.
Several other studies examined associations of clinical
outcomes and sociodemographic factors in women with
breast cancer who received neoadjuvant chemotherapy. In a
pooled analysis of data from four prospective clinical trials,
Warner et al123 found that ethnicity (Hispanic v non-
Hispanic) and race (African American v White) were not
significant predictors of pCR rate. Tichy et al121 similarly
observed no significant differences in pCR rate by race in a
cohort of women with stage II-III breast cancer who received
the same neoadjuvant treatment. In their multivariable
analysis, worse time to recurrence was found among African
American women, but only in those women with HR-positive
disease (HR, 1.85; 95% CI, 1.09 to 3.14). There was no
difference between OS by race. Finally, in a study of patients
with breast cancer who received anthracycline- and taxane-
based neoadjuvant chemotherapy, Chavez-MacGregor
et al127 found no differences in pCR rates among race or
ethnicity subgroups (12.3% in Blacks, 14.2% in Hispanics,
12.3% in Whites, and 11.5% in others, P5 .788). However,
compared with White patients, Hispanic patients had im-
proved recurrence-free survival (HR, 0.69; 95% CI, 0.49 to
0.97) and OS (HR, 0.63; 95% CI, 0.41 to 0.97).
It is possible that for some patients, especially those with
poor access to the multiple healthcare providers involved in
breast cancer care, earlier initiation of therapy may reduce
delays in care. Delays in care have been associated with poor
breast cancer outcomes among minorities and patients with
low socioeconomic status,128 particularly those with TNBC.
Research is underway to determine whether reducing delays
in care for high-risk women by early administration of
neoadjuvant chemotherapy improves outcomes.
COST IMPLICATIONS
Increasingly, individuals with cancer are required to pay a
larger proportion of their treatment costs through deduct-
ibles and coinsurance.129,130 Higher patient out-of-pocket
costs have been shown to be a barrier to initiating and
adhering to recommended cancer treatments.131,132
Discussion of cost can be an important part of shared
decision making.133 Clinicians should discuss with patients
the use of less expensive alternatives when it is practical
and feasible for treatment of the patient’s disease and there
are two or more treatment options that are comparable in
terms of benefits and harms.133
Patient out-of-pocket costs may vary depending on in-
surance coverage. Coveragemay originate in themedical or
pharmacy benefit, which may have different cost-sharing
arrangements. Patients should be aware that different
products may be preferred or covered by their particular
insurance plan. Even with the same insurance plan, the
price may vary between different pharmacies. When dis-
cussing financial issues and concerns, patients should be
made aware of any financial counseling services available
to address this complex and heterogeneous landscape.133
As part of the guideline development process, ASCO may
opt to search the literature for published cost effectiveness
analyses that might inform the relative value of available
treatment options. Excluded from consideration are cost-
effective analyses that lack contemporary cost data; agents
that are not currently available in either the United States or
Canada; and/or are industry-sponsored. The targeted lit-
erature search conducted for this guideline identified no
cost-effectiveness analyses that satisfied the inclusion
criteria. The decision of giving a treatment in the adjuvant or
neoadjuvant setting does not alter the overall costs of care;
however, limiting the extent of surgery, introducing radia-
tion, and extending therapy after neoadjuvant therapy do
have the potential to alter the total financial burden.
OPEN COMMENT
The draft recommendations were released to the public for
open comment from August 28, 2020, through September 8,
2020. Response categories of “Agree as written,” “Agree with
suggested modifications,” and “Disagree. See comments”
were captured for every proposed recommendation with 41
written comments received. A total of six (55%) of the 11
respondents either agreed or agreed with slight modifications
to the recommendations and five (45%) of the respondents
disagreed with one or more of the draft recommendations.
The most common point of disagreement concerned the use
of genomic profile markers to guide neoadjuvant therapy
clinical decision making. Expert Panel members reviewed
comments from all sources and determined whether to
maintain original draft recommendations, revise with minor
language changes, or consider major recommendation re-
visions. All changes were incorporated prior to Clinical
Practice Guidelines Committee review and approval.
GUIDELINE IMPLEMENTATION
ASCO guidelines are developed for implementation across
health settings. Each ASCO guideline includes a member
from ASCO’s Practice Guideline Implementation Network
(PGIN) on the panel. The additional role of this PGIN
representative on the guideline panel is to assess the
suitability of the recommendations to implementation in the
community setting, but also to identify any other barrier to
implementation of which a reader should be aware. Bar-
riers to implementation include the need to increase
awareness of the guideline recommendations among front-
line practitioners and survivors of cancer and caregivers,
and also to provide adequate services in the face of limited
resources. The guideline Bottom Line Box was designed to
facilitate implementation of recommendations. This
guideline will be distributed widely through the ASCO PGIN.
ASCO guidelines are posted on the ASCO website and most
often published in the Journal of Clinical Oncology.
ASCO believes that cancer clinical trials are vital to inform
medical decisions and improve cancer care, and that all
patients should have the opportunity to participate.
ADDITIONAL RESOURCES
More information, including a supplement with additional
evidence tables, slide sets, and clinical tools and resources,
is available at www.asco.org/breast-cancer-guidelines.
Patient information is available at www.cancer.net.
RELATED ASCO GUIDELINES
• Integration of Palliative Care into Standard On-
cology Practice134 (http://ascopubs.org/doi/
10.1200/JCO.2016.70.1474)
• Patient-Clinician Communication112 (http://
ascopubs.org/doi/10.1200/JCO.2017.75.2311)
• Selection of Optimal Adjuvant Chemotherapy
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